Zekai Shu1, Baiqiang Dong2, Lei Shi3, Wei Shen3, Qingqing Hang1, Jin Wang4,5, Yuanyuan Chen6,7. 1. The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, 310053, China. 2. School of Radiation Medicine and Protection, Medical College of Soochow University, Suzhou, 215123, China. 3. Hangzhou YITU Healthcare Technology Co., Ltd, Hangzhou, 310012, China. 4. Institute of Cancer Research and Basic Medical Sciences, Chinese Academy of Sciences, Hangzhou, 310011, China. wangjin@zjcc.org.cn. 5. Department of Radiation Oncology, Cancer Hospital of University of Chinese Academy of Sciences, Hangzhou, 310011, China. wangjin@zjcc.org.cn. 6. Institute of Cancer Research and Basic Medical Sciences, Chinese Academy of Sciences, Hangzhou, 310011, China. chenyy@zjcc.org.cn. 7. Department of Radiation Oncology, Cancer Hospital of University of Chinese Academy of Sciences, Hangzhou, 310011, China. chenyy@zjcc.org.cn.
Abstract
PURPOSE: Stereotactic body radiotherapy (SBRT) is the primary treatment method for early-stage non-small cell lung cancer (NSCLC) considered inoperable due to medical comorbidities. However, the application of SBRT in patients aged ≥ 75 years has not been adequately studied. This retrospective study aimed to investigate the effectiveness and safety of SBRT in early-stage NSCLC patients aged ≥ 75 years, and the impact of treatment on nutritional status and self-care ability. METHODS: Histopathologically confirmed early-stage (T1-3N0M0) NSCLC patients aged ≥ 75 years treated with SBRT between 2013 and 2018 at our center were identified from the electronic database. Treatment efficacy, treatment toxicities, impact of treatment on nutritional status, and self-care ability were retrospectively analyzed. Toxicities were evaluated according to the Common Terminology Criteria for Adverse Event (CTCAE) (Common 2010) version 4.0. Nutritional status was assessed by Nutritional Risk Screening 2002 criteria, and self-care ability by Barthel index and fall risk index. RESULTS: A total of 68 patients were enrolled. Median follow-up duration was 46.3 (3.9-80.1) months. The 1-, 3-, and 5-year overall survival rates were 92.6%, 77.2%, and 59.1%, respectively, and the 1-year, 3-year and 5-year local control rates were 95.6%, 88.9% and 85.6%, respectively. Grade 1-2 and grade 3 radiation pneumonitis occurred in 60/68 (96.8%) and 1/68 (1.5%) patients, respectively. Fall risk at 3 months after treatment was not significantly different from that before treatment (P = 0.22). Barthel index increased significantly after treatment (P < 0.001). CONCLUSIONS: SBRT appears to be effective and safe for NSCLC patients aged ≥ 75 years, with no adverse impact on nutritional status and self-care ability.
PURPOSE: Stereotactic body radiotherapy (SBRT) is the primary treatment method for early-stage non-small cell lung cancer (NSCLC) considered inoperable due to medical comorbidities. However, the application of SBRT in patients aged ≥ 75 years has not been adequately studied. This retrospective study aimed to investigate the effectiveness and safety of SBRT in early-stage NSCLC patients aged ≥ 75 years, and the impact of treatment on nutritional status and self-care ability. METHODS: Histopathologically confirmed early-stage (T1-3N0M0) NSCLC patients aged ≥ 75 years treated with SBRT between 2013 and 2018 at our center were identified from the electronic database. Treatment efficacy, treatment toxicities, impact of treatment on nutritional status, and self-care ability were retrospectively analyzed. Toxicities were evaluated according to the Common Terminology Criteria for Adverse Event (CTCAE) (Common 2010) version 4.0. Nutritional status was assessed by Nutritional Risk Screening 2002 criteria, and self-care ability by Barthel index and fall risk index. RESULTS: A total of 68 patients were enrolled. Median follow-up duration was 46.3 (3.9-80.1) months. The 1-, 3-, and 5-year overall survival rates were 92.6%, 77.2%, and 59.1%, respectively, and the 1-year, 3-year and 5-year local control rates were 95.6%, 88.9% and 85.6%, respectively. Grade 1-2 and grade 3 radiation pneumonitis occurred in 60/68 (96.8%) and 1/68 (1.5%) patients, respectively. Fall risk at 3 months after treatment was not significantly different from that before treatment (P = 0.22). Barthel index increased significantly after treatment (P < 0.001). CONCLUSIONS: SBRT appears to be effective and safe for NSCLC patients aged ≥ 75 years, with no adverse impact on nutritional status and self-care ability.
Authors: K L Perell; A Nelson; R L Goldman; S L Luther; N Prieto-Lewis; L Z Rubenstein Journal: J Gerontol A Biol Sci Med Sci Date: 2001-12 Impact factor: 6.053
Authors: Andrea Bezjak; Rebecca Paulus; Laurie E Gaspar; Robert D Timmerman; William L Straube; William F Ryan; Yolanda I Garces; Anthony T Pu; Anurag K Singh; Gregory M Videtic; Ronald C McGarry; Puneeth Iyengar; Jason R Pantarotto; James J Urbanic; Alexander Y Sun; Megan E Daly; Inga S Grills; Paul Sperduto; Daniel P Normolle; Jeffrey D Bradley; Hak Choy Journal: J Clin Oncol Date: 2019-04-03 Impact factor: 44.544
Authors: Shervin M Shirvani; Jing Jiang; Joe Y Chang; James W Welsh; Daniel R Gomez; Stephen Swisher; Thomas A Buchholz; Benjamin D Smith Journal: Int J Radiat Oncol Biol Phys Date: 2012-09-11 Impact factor: 7.038
Authors: Gregory M M Videtic; Jessica Donington; Meredith Giuliani; John Heinzerling; Tomer Z Karas; Chris R Kelsey; Brian E Lally; Karen Latzka; Simon S Lo; Drew Moghanaki; Benjamin Movsas; Andreas Rimner; Michael Roach; George Rodrigues; Shervin M Shirvani; Charles B Simone; Robert Timmerman; Megan E Daly Journal: Pract Radiat Oncol Date: 2017-06-05
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Benjamin D Smith; Grace L Smith; Arti Hurria; Gabriel N Hortobagyi; Thomas A Buchholz Journal: J Clin Oncol Date: 2009-04-29 Impact factor: 44.544
Authors: Janneke P C Grutters; Alfons G H Kessels; Madelon Pijls-Johannesma; Dirk De Ruysscher; Manuela A Joore; Philippe Lambin Journal: Radiother Oncol Date: 2009-09-03 Impact factor: 6.280